Exabis Library
Welcome to the e-CCO Library!
DOP01: A multi-centre study to explore the prevalence of Inflammatory Bowel Disease indicators in patients with moderate- to- severe psoriasis: Baseline results from the EPIC study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
Friday, 4 March 2022, 1:45 PM by Dietrich Diz Angerer-GTN
DOP01: Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP01: Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP01: Exclusive enteral nutrition for treatment of Adult Crohn's Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP01: Exclusive enteral nutrition for treatment of Adult Crohn's Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP01: Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): possible new target and biomarker in inflammatory bowel diseases
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP01: The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP01: The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumab
2017
ECCO'17 Barcelona
1
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn’s disease: pooled results from the ASTIC trial
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP020: Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological era
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP020:Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn’s Disease in the biological era
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s disease: 10-year follow-up data from the Swiss IBD cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s Disease: 10-year-follow-up data from the Swiss IBD cohort study
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn’s Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
2017
ECCO'17 Barcelona
1